Crestline Management, L.P.
Crestline Management, L.P. reported 3 US-listed holdings worth $53.5 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Denali Therapeutics Inc. (91.9%), Sana Biotechnology Inc. (4.9%) and 8X8 Inc. New (3.2%). Against the quarter before, it opened 0 positions, added to 0, trimmed 1 and sold out of 0.
Filed before as Crestline Management, LP.
The 3 largest of its 3 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +74.2% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Trimmed 1
- Denali Therapeutics Inc. DNLI-300,000 shares · -14%
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Denali Therapeutics Inc. DNLI | 1.9M | $49.1 million | 91.90% | -300.0K |
| Sana Biotechnology Inc. SANA | 755.7K | $2.6 million | 4.93% | no change |
| 8X8 Inc. New EGHT | 990.9K | $1.7 million | 3.17% | no change |